Low molecular weight heparins and bleeding.
Breddin
H K
HK
Department of Internal Medicine, J. W. Goethe-University, Frankfurt/Main, FRG.
D000818:Animals; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000633:toxicity; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D006496:Heparinoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011817:Rabbits; D051381:Rats; D013924:Thrombophlebitis / Q000517:prevention & control
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D006493:Heparin